tbuckley/cabot-search huggingface dataset:
Abstract 699: HSP70 specifically binds to 15 bp deletion mutant EGFR and modulates sensitivity to EGFR-TKI
Authors: Tsuyoki Kadofuku, Tomoko Kanome, Yoko Ichihashi, Toshimitsu Yamaoka, Takashi Hirose, Mitsuru Adachi, Nagahiro Saijo, Tohru Ohmori
Journal: Cancer Research (2011)

Abstract [Purpose] Non small lung cancer (NSCLC) cells that expressed mutant EGFR are more sensitive to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) than that expressed wild type EGFR. Recent clinical trials revealed that more than 70% NSCLC patients that expressed mutant EGFR showed sensitivity to EGFR-TKIs, such as gefitinib and erlotinib. To elucidate the mechanism of this hypersensitivity, we explored the difference of EGFR-binding proteins between wild type EGFR and 15 bp deletion mutant EGFR using respective stable transfectants. [Methods] Wild type EGFR and a 15 bp deletion mutant EGFR plasmids were transfected into HEK293 cells. The stable transfectant cells were established, and were designated 293_pEGFR and 293_pΔ15, respectively. Cells were incubated in a medium with/without 10 ng/ml of TGFα for 1 h and lysed. Cell lysate was precleared by centrifugation at 15,000 rpm for 15 min. The supernatant was mixed with a polyclonal EGFR antibody for 1 h and EGFR was immunoprecipitated by Protein A-Sepharose. After adequate washing, coprecipitated proteins that bound to EGFR were eluted and separated by 2D-PAGE (Immobiline DryStrip (pH3-10 NL, 7 cm) and 10% SDS-PAGE). Proteins were visualized by silver staining and identified by LC-MS/MS. HSP70 siRNA was transfected into the cells by lipofection method. Sensitivity to gefitinib was measured by MTT assay. EGFR binding affinity to gefitinib was measured using [14C] gefitinib. [Results and Discussion] We detected several EGFR binding proteins. Among these proteins, one candidate (lesser binding to wild type EGFR than the mutant EGFR) was identified as HSP 70 by LC-MS/MS. The total amount of HSP70 protein was not different between 293_pEGFR and293_pΔ15 cells. A specific binding of this protein to the mutant EGFR was confirmed by Western blotting analysis. This binding was not modulated by EGFR activation. Knockdown of HSP 70 protein by a specific siRNA enhanced gefitinib sensitivity in the mutant EGFR transfectant. These results suggest that HSP 70 may decrease sensitivity to EGFR-TKIs in the cells that expressed 15 bp deletion mutant EGFR. There is a possibility that HSP70 overexpression might be a newly resistant mechanism to EGFR-TKIs in NSCLC patients that expressed mutant EGFR. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 699. doi:10.1158/1538-7445.AM2011-699
TCT-716 Outcomes Of Percutaneous Mitral Valve Repair In Patients With Chronic Kidney Disease¦ Results From A Multi-Center Registry
Authors: Neha Maheshwari, Gagan D. Singh, Jonathan Yap, Khung K. Yeo, Jose F. Condado, Benjamin Stripe, Vasilis Babaliaros, Dan Arnett, James M. McCabe, Mark Reisman, Thomas Smith, Dali Fan, Reginald Low, Jason H. Rogers
Journal: Journal of the American College of Cardiology (2015)
Cancer prevention and therapy through the modulation of transcription factors by bioactive natural compounds
Authors: Muthu K Shanmugam, Jong Hyun Lee, Edna Zhi Pei Chai, Madhu Mathi Kanchi, Shreya Kar, Frank Arfuso, Arunasalam Dharmarajan, Alan Prem Kumar, Perumal Samy Ramar, Chung Yeng Looi, Mohammad Rais Mustafa, Vinay Tergaonkar, Anupam Bishayee, Kwang Seok Ahn, Gautam Sethi
Journal: Seminars in Cancer Biology (2016)
Expression Pattern of MRP in Human Tissues and Adult Solid Tumor Cell Lines
Authors: G. D. Kruh, K. T. Gaughan, A. Godwin, A. Chan
Journal: JNCI Journal of the National Cancer Institute (1995)

Journal Article Expression Pattern of MRP in Human Tissues and Adult Solid Tumor Cell Lines Get access Gary D. Kruh, Gary D. Kruh Department of Medical Oncology, Fox Chase Cancer CenterPhiladelphia, PA Search for other works by this author on: Oxford Academic PubMed Google Scholar Katheleen T. Gaughan, Katheleen T. Gaughan Department of Medical Oncology, Fox Chase Cancer CenterPhiladelphia, PA Search for other works by this author on: Oxford Academic PubMed Google Scholar Andrew Godwin, Andrew Godwin Department of Medical Oncology, Fox Chase Cancer CenterPhiladelphia, PA Search for other works by this author on: Oxford Academic PubMed Google Scholar Andrew Chan Andrew Chan The Derald H. Ruttenberg Cancer CenterNew York, NY Correspondence to: Gary D. Kruh, M.D., Department of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme Ave., Philadelphia, PA 19111. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 87, Issue 16, 16 August 1995, Pages 1256–1260, https://doi.org/10.1093/jnci/87.16.1256 Published: 16 August 1995 Article history Received: 22 March 1995 Revision received: 16 May 1995 Accepted: 05 June 1995 Published: 16 August 1995
Abstract P2-05-11: Proteomic identification and in-silico verification of subtype-specific signatures in breast cancer.
Authors: MP Pavlou, A Dimitromanolakis, EP Diamandis
Journal: Cancer Research (2012)

Abstract Breast cancer is a highly heterogeneous disease with different subtypes presenting distinct clinical characteristics. During the last decade has been shown that molecular classification of breast cancer holds the promise for the development of novel prognostic tools and the identification of novel treatment targets. However, proteins are the main mediators of biological processes and the molecular targets of the majority of drugs. Moreover, the proteome integrates the cellular genetic information and environmental influences. Hence coupling proteomic and transcriptomic studies may augment the development of targeted therapies and the identification of disease-relevant proteins networks. Here, we report an extensive mass spectrometry-based (MS) secretome analysis of eight breast cancer cell lines representing, the three main breast cancer subtypes (luminal, basal and HER2-neu amplified) in search of subtype-specific proteomic signatures. Following a bottom-up proteomic approach coupled to tandem mass spectrometry the conditioned media of 8 breast cancer cell lines were analyzed. More than 5,200 non-redundant proteins were identified in the conditioned media of the 8 cell lines with a false positive rate less than 1%. The mass spectrometry-based identification of 5 proteins was successfully verified by ELISA. For the generation of subtype-specific proteomic signatures, proteins common to all cell lines of the same subtype but not present in the other two subtypes were identified. Twenty-three, four and four proteins were found uniquely in basal, HER2-neu amplified and luminal breast cancer cells. Notably, ERBB2 was one of the proteins uniquely identified in the HER2-neu amplified subtype verifying the validity of our approach. Given that most of these proteins have no quantitative methods available at present, we opted to preliminarily examine the relationship of these candidates with breast cancer subtypes by using an in silico approach, based on transcriptomic data. We performed an in silico mRNA expression analysis using publicly available data from four independent experiments containing a total of 1039 patients with primary breast cancer. The expression profiles of 15 of 31 proteins investigated showed significant correlation with estrogen receptor expression and power to distinguish subtypes. The development of multiplex quantitative mass spectrometry-based assays for the quantification of the proteomic signatures in relevant biological specimens along with immunohistochemical studies for two of the 31 candidates are currently ongoing. The significance of these subtype-specific proteins in breast cancer prognosis and disease progression warrants further investigation. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-05-11.
619 THE ROAD TO A SUCCESSFUL TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) SERVICE: EXPERIENCE OF A UK TEACHING HOSPITAL
Authors: R.B. McCorry, E.A. Wilkes, R. O'Neil, G.P. Aithal, S.D. Ryder, I.N. Guha, M.W. James
Journal: Journal of Hepatology (2013)
Recurrent Dermatofibrosarcoma Protuberans With Pulmonary Metastases Presenting Twelve Years After Initial Diagnosis
Authors: Sudhir Suman, Punit Sharma, Tarun Kumar Jain, Manas Kumar Sahoo, Chandrasekhar Bal, Rakesh Kumar
Journal: Clinical Nuclear Medicine (2013)

Dermatofibrosarcoma protuberans is a rare cutaneous tumor that is locally aggressive and has a high rate of recurrence after surgical excision. The tumor grows slowly, typically over years. On rare occasions, metastasis to distant sites (especially the lung) or regional lymph nodes may occur. Here, we present F-FDG PET/CT imaging findings of a 52-year-old man with a local recurrence of dermatofibrosarcoma protuberans in the anterior abdominal wall with metastases to bilateral lungs.
Nonbacterial Regional Lymphadenitis (Cat-Scratch Fever)
Authors: Joseph J. McGovern, Lawrence J. Kunz, Frederic M. Blodgett
Journal: New England Journal of Medicine (1955)

DURING the period October, 1953, through February, 1954, the diagnosis of nonbacterial regional lymphadenitis was made in 18 patients at the Massachusetts General Hospital. An intradermal-test antigen was used in each of the cases, giving rise to theoretical questions concerning the sensitivity and diagnostic significance of the intradermal test. Since the literature does not contain any reports of an extensive study of tests with this antigen in normal people an investigation of its value was carried out. The present report summarizes the results obtained with a limited supply of antigen and indicates the need for further study of the problem. . . .
Cancer Incidence in the Families of Children With Ewing's Tumor
Authors: A. L. Hartley, J. M. Birch, V. Blair, M. D. Teare, H. B. Marsden, M. Harris
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Cancer Incidence in the Families of Children With Ewing's Tumor Get access A. L. Hartley, A. L. Hartley * 1Cancer Research Campaign Paediatric and Familial Cancer Research Group Christie Hospital and Holt Radium InstituteManchester, England * Correspondence to: A. L. Hartley, Cancer Research Campaign Paediartic and Familial Cancer Research Group, Christie Hospital and Holt Radium Institute, Wilmslow Rd., Manchester M20 9BX, England. Search for other works by this author on: Oxford Academic PubMed Google Scholar J. M. Birch, J. M. Birch 1Cancer Research Campaign Paediatric and Familial Cancer Research Group Christie Hospital and Holt Radium InstituteManchester, England Search for other works by this author on: Oxford Academic PubMed Google Scholar V. Blair, V. Blair 1Cancer Research Campaign Paediatric and Familial Cancer Research Group Christie Hospital and Holt Radium InstituteManchester, England Search for other works by this author on: Oxford Academic PubMed Google Scholar M. D. Teare, M. D. Teare 1Cancer Research Campaign Paediatric and Familial Cancer Research Group Christie Hospital and Holt Radium InstituteManchester, England Search for other works by this author on: Oxford Academic PubMed Google Scholar H. B. Marsden, H. B. Marsden 2Cancer Research Campaign Paediatric and Familial Cancer Research Group Christie Hospital and Holt Radium InstituteManchester, England Search for other works by this author on: Oxford Academic PubMed Google Scholar M. Harris M. Harris 3Department of Pathology, Christie Hospital and Holt Radium InstituteManchester, England Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 13, 3 July 1991, Pages 955–957, https://doi.org/10.1093/jnci/83.13.955 Published: 03 July 1991 Article history Received: 03 December 1990 Revision received: 01 April 1991 Accepted: 18 April 1991 Published: 03 July 1991
AB0959 The Role of Ultrasonography in the Early Diagnosis of Arthropathy in A not Target Joint of Haemophiliacs
Authors: D. Melchiorre, S. Linari, M. Morfini, F. Bandinelli, M. Matucci-Cerinic
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> The hip is not a target joint in haemophilic arthropathy (HA). Patients (pts) with Haemophilia have hip pain without obvious signs of joint involvement. They have, very often, haematoma or bursitis. <h3>Objectives</h3> To investigate the role of ultrasonography (US) to detect bleeding and joint damage HA of the hip. <h3>Methods</h3> In 30 pts, with Haemophilia and monolateral hip pain, the iliopsoas and its bursa, the greater trochanteric bursae, and the joint were studied by US. The 30 joints were evaluated and scored (score ranging from 0 to 21) for effusion, bone remodelling, cartilage damage, synovial hypertrophy, haemosiderin, osteophytes, haemarthrosis, erosion and fibrotic septa. The clinical evaluation [World Federation Haemophiliac orthopaedic score (WFHO)] was done in all pts. Power Doppler US (PDUS) was performed in all patients. <h3>Results</h3> US showed effusion in 20 joints, bone remodelling in 18, cartilage damage in 10, synovial hypertrophy in 12, haemosiderin in 4, osteophytes in 7, haemarthrosis in 10 with PDUS activity, erosion in 0 and fibrotic septa in 0. In haemophiliacs 15 out of 30 joints showed US score ≤5, and 15 US score &gt;5 (1,2). In 8 pts was present haematoma of iliopsoas, in two pts great trocanteric bursitis. <h3>Conclusions</h3> US detected bone and cartilage alterations and synovitis in the hip. Indeed PDUS identified the bleeding in the joints and was able to show different entity of haemarthrosis. US may be useful to evaluate joint modifications in HA in no target joint, too. <h3>References</h3> Melchiorre D, et al. Haemophilia 2011,17:112-7 Querol F, et al. Haemophilia 2012,18:e215-e226 <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4391
Colonic findings in Churg-Strauss syndrome
Authors: T. Yoshioka, T. Kusaka, H. Seno
Journal: Endoscopy (2013)

A 66-year-old woman presented with nausea, loss of appetite, fever, and abdominal pain. She had livedo reticularis on the anterior surfaces of both legs ([Fig. 1]). Her medical history included asthma, drug allergy, and sinusitis. Laboratory tests revealed marked eosinophilia (14.8 × 109/L), anemia (hemoglobin 10.9 g/dL), inflammation (C-reactive protein [CRP] 7.4 mg/dL), high levels of rheumatoid factor (3561 IU/mL) and serum IgE (1130 IU/mL), but normal myeloperoxidase (MPO)-antineutrophil cytoplasmic antibody (ANCA) and proteinase 3 (PR3)-ANCA. Examination of the stool did not reveal any parasites.
THU0582-HPR What is Known about Rheumatoid Arthritis Patients' Support Needs for Self-Management? A Scoping Review
Authors: R. Zuidema, B. van Gaal, H. Repping-Wuts, A. Evers, T. van Achterberg
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Patients with Rheumatoid Arthritis (RA) face several problems due to their disease, such as pain, fatigue, anxiety, which have consequences in their daily life. Self-management programs can support patients to manage these consequences. To build a patient focused self-management program, insight in support needs from the patient9s perspective is important. Currently, insight in these support needs is lacking. <h3>Objectives</h3> To perform a scoping review on the support needs for self-management as formulated by RA patients <h3>Methods</h3> We conducted a scoping review according to the steps of Levac et al (2010) with the following research question: <i>what are the support needs for self-management from a patient perspective?</i> We searched Pubmed, CINAHL and PsychInfo in May 2013 for studies from last ten years. We searched Pubmed, CINAHL and PsychInfo in May 2013 for studies from the last ten years. Of the 642 studies retrieved, 20 were considered relevant. We also consulted patients from our development group to reflect on the results of our literature review. <h3>Results</h3> Based on the preliminary outcomes, we made a distinction between (1) information needs (e.g information about medication and performing exercises) and (2) support from peers, professionals and colleagues (e.g. support at work through colleagues or support of peers because of the mutual recognition). We divided these support needs in the areas of consequences of the disease, namely: (1) physical consequences, (2) psychological consequences, (3) social consequences, (4) daily life consequences and (5) work consequences. <h3>Conclusions</h3> This study offers an overview of support needs for self-management from RA patients9 perspective, which can help to build a patient focused self-management program. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4222
IN HOSPITAL USE OF NON-STEROIDAL ANTI-INFLAMMATORY AGENTS IN PATIENTS WITH A PRINCIPAL DIAGNOSIS OF HEART FAILURE IS ASSOCIATED WITH INCREASED LENGTH OF STAY AND 30-DAY READMISSION RATE
Authors: Paulino Alvarez, David Putney, Richard Ogunti, Stephen Wong, Mamta Puppala, Robert Schutt, Jerry Estep
Journal: Journal of the American College of Cardiology (2016)
Abstract 42: Biological significance of the lipogenic enzyme acetyl-CoA carboxylase in the control of metastatic properties of murine and human transformed cells
Authors: Kristen E. Scott, Frances B. Wheeler, James M. Ntambi, Darren F. Seals, Steven J. Kridel
Journal: Cancer Research (2010)

Abstract In recent years, it has been determined that the fatty acid synthesis pathway is upregulated in several types of cancers of epithelial origin at both transcriptional and translational levels. Unlike normal cells, cancer cells rely on this pathway to provide the fatty acid precursors needed for synthesizing lipids that preferentially segregate into the liquid ordered microdomains of the plasma membrane. Acetyl-CoA carboxylase (ACC) is the ATP dependent and rate limiting step of fatty acid synthesis and catalyzes the carboxylation of acetyl-CoA to malonyl-CoA. Interestingly, overexpression of this enzyme increases with severity of breast cancer patient samples and cell lines, indicating a possible role for ACC in the metastatic process. Preliminary findings from our lab indicate that ACC is important for the proteolytic invasion and migration of transformed cells independently of cell death. Moreover, ACC is critical for formation of F-actin rich membrane structures known as podosomes, which have been implicated in the metastatic process in recent years. Restoration of podosomes in cells with ACC inhibition was achieved with the addition of the soluble fatty acid, C18:1 (oleate). In contrast, inhibition of the fatty acid synthetic enzyme, fatty acid synthase (FASN), or the Δ9 desaturase, stearoyl-CoA desaturase 1 (SCD-1), does not affect podosome formation. However, inhibition of FASN resulted in attenuated proteolytic invasion and migration of transformed cells with a phenotype similar to cells with ACC inhibition although not quite to the same degree. In addition to regulation at transcriptional and translational levels, ACC activity is also regulated by phosphorylation/dephosphorylation by AMP activated protein kinase (AMPK). Decreased ACC phosphorylation at serine 79 (S79) has been shown to correlate with increased disease severity and reduced disease free survival of lung adenocarcinoma patients. This indicates that the phosphorylation status of ACC may be an important mechanism that cancer cells manipulate to successfully achieve metastasis. Therefore, induction of phosphorylation, and inactivation of ACC, either by activation of AMPK or by direct mutation of S79 may be sufficient to reduce invasion and migration of cancer cells. Taken together, investigating ACC phosphorylation status and analyzing the resulting phenotype will advance the mechanistic understanding of how cancer cells metastasize and possibly provide new therapeutic avenues to explore in the treatment of disseminated disease. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 42.
Value of Lymph-Node Biopsy in the Diagnosis of Acute Acquired Toxoplasmosis
Authors: Ronald F. Dorfman, Jack S. Remington
Journal: New England Journal of Medicine (1973)

The histologic findings supporting a diagnosis of toxoplasmic lymphadenitis, in lymph-node biopsies from 31 patients, were correlated with serologic studies. The Sabin-Feldman dye test was positive in all cases, with titers ranging from 1024 to 32,768; 81 per cent were 4096 or greater. The IgM immunofluorescent-antibody test was positive in 97 per cent of these cases. In contrast only 24 per cent of 114 patients with malignant lymphoma showed a positive dye test, with titers ranging from 4 to 1024, and only two exceeding 256, and only one patient was positive in the IgM immunofluorescent-antibody test. Of 87 surgical patients, the dye test was positive in 36 per cent, the range of titers varying from 16 to 2048, only five exceeding 256 and only one patient showing a positive IgM immunofluorescent-antibody test. These results provide further evidence of the distinctive nature of the histologic changes in toxoplasmic lymphadenitis, which should enable the pathologist to make a confident diagnosis of acute acquired toxoplasmosis. This study also emphasizes the need for clinicians to consider toxoplasmosis in the differential diagnosis of lymphadenopathy. (N Engl J Med 289:878–881, 1973)
Further studies are needed on novel covered antireflux metallic stents
Authors: Yucel Ustundag, Ulku Saritas, Mohamad Eloubeidi
Journal: Endoscopy (2014)

We read with interest the article by Hu et al. [1] about the success of modified metal stents with an antireflux function (ARMS) in preventing ascending cholangitis in patients with malignant biliary strictures. In their study, the authors compared newly designed partially covered ARMSs with uncovered self-expandable metal stents (ucSEMSs) with regard to the rate and frequency of cholangitis and stent patency. They noted a significantly lower rate and frequency of cholangitis in the ARMS group than in the ucSEMS group (18 % vs. 38 %; P = 0.035) and (1.9 % vs. 16 %; P = 0.022), respectively. There was also a higher median patency rate in the ARMS group compared with the ucSEMS group (13 months vs. 10 months; P = 0.044).
Induction of IL-10 Production by Dendritic Cells From a Human Myeloblast Cell Line and Peripheral Blood Mononuclear Cells From Asthmatic Patients by an Alkaloid Compound From Sophorae Flavescentis
Authors: William Holder, Changda Liu, Ying Song, Nan Yang, Jody R. Tversky, Xiu-Min Li
Journal: Journal of Allergy and Clinical Immunology (2013)